: Non-alcoholic fatty liver disease (NAFLD) is currently the fastest growing indication to liver transplantation (LT) in Western Counties, both for end stage liver disease (ESLD) and hepatocellular carcinoma (HCC). NAFLD/NASH is often expression of a systemic metabolic syndrome; therefore, NAFLD/NASH patients require a multidisciplinary approach for a proper pre-surgical evaluation, which is important to achieve a post-transplant outcome comparable to that of other indications to LT. NAFLD/NASH patients are also at higher risk of post-transplant cardiovascular (CV) events, diabetes, dyslipidemia, obesity, renal impairment and recurrent NASH. Lifestyle modifications, included diet and physical activity, are key to improve survival and qualit...
Liver transplant is the unique curative therapy for patients with acute liver failure or end-stage l...
Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic fatty li...
The metabolic syndrome (MS), which includes obesity, dyslipidaemia, hypertension and hyperglycaemia ...
Non-alcoholic fatty liver disease (NAFLD), specifically its progressive form non-alcoholic steatohep...
The rising tide of non-alcoholic fatty liver disease (NAFLD) associated with the obesity epidemic is...
Non-alcoholic fatty liver disease (NAFLD), specifically its progressive form non-alcoholic steatohep...
In the last years, nonalcoholic steatohepatitis (NASH) has become a leading indication for liver tra...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in many c...
Nonalcoholic fatty liver disease (NAFLD) represents one of the most diffuse liver diseases worldwide...
Non-alcoholic fatty liver disease (NAFLD) is a frequent etiology of liver disease in Western Countri...
Nonalcoholic steatohepatitis (NASH) is a growing indication for liver transplant whether the primary...
Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recen...
Non-alcoholic steatohepatitis is a growing liver-related health problem. In Europe, non-alcoholic fa...
Nonalcoholic fatty liver disease (NAFLD) is characterized by histological evidence of hepatic steato...
Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is a challenging and mult...
Liver transplant is the unique curative therapy for patients with acute liver failure or end-stage l...
Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic fatty li...
The metabolic syndrome (MS), which includes obesity, dyslipidaemia, hypertension and hyperglycaemia ...
Non-alcoholic fatty liver disease (NAFLD), specifically its progressive form non-alcoholic steatohep...
The rising tide of non-alcoholic fatty liver disease (NAFLD) associated with the obesity epidemic is...
Non-alcoholic fatty liver disease (NAFLD), specifically its progressive form non-alcoholic steatohep...
In the last years, nonalcoholic steatohepatitis (NASH) has become a leading indication for liver tra...
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in many c...
Nonalcoholic fatty liver disease (NAFLD) represents one of the most diffuse liver diseases worldwide...
Non-alcoholic fatty liver disease (NAFLD) is a frequent etiology of liver disease in Western Countri...
Nonalcoholic steatohepatitis (NASH) is a growing indication for liver transplant whether the primary...
Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recen...
Non-alcoholic steatohepatitis is a growing liver-related health problem. In Europe, non-alcoholic fa...
Nonalcoholic fatty liver disease (NAFLD) is characterized by histological evidence of hepatic steato...
Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) is a challenging and mult...
Liver transplant is the unique curative therapy for patients with acute liver failure or end-stage l...
Because of global epidemics of obesity and type 2 diabetes, the prevalence of non-alcoholic fatty li...
The metabolic syndrome (MS), which includes obesity, dyslipidaemia, hypertension and hyperglycaemia ...